Ebos Group Ltd EBO

Morningstar Rating
NZD 36.90 0.00 (0.00%)
View Full Chart

Company Report

Ebos' Scale Has It Leading the Pack, but Shares Screen as Expensive

Australia’s Pharmaceutical Benefits Scheme, or PBS, drug wholesalers face regulation that caps gross margins for distributed drugs at 7% for community pharmacy and 10% for hospitals, as well as ongoing price reform which lowers the prices for these drugs. However, Ebos is best placed within the industry. Its superior scale and efficiency of operations translate into better operating margins than peers and an ability to earn economic profits at a time when competitors are falling short. We do not anticipate the Australian government to make any major changes to the PBS. We forecast industry PBS-related wholesale and distribution revenue to increase at approximately 1.5% per year, in line with population growth estimates, and the major participants to at least broadly maintain their existing market shares.

Price vs Fair Value

EBO is trading at a 126% premium.
Price
NZD 36.90
Fair Value
NZD 99.40
Uncertainty
Medium
1-Star Price
NZD 47.83
5-Star Price
NZD 35.35
Economic Moat
Npnsjl
Capital Allocation
Fypfzmjtb

Bulls Say, Bears Say

Bulls

None of the competitors can replicate Ebos’ combined scale across community pharmacy and institutional drug distribution and as a result we believe its relative cost advantage should persist.

Bears

The large holding by the Sybos Group provides an overhang as its sale would likely put downward pressure on the share price.

Trading Information

Previous Close Price
NZD 36.90
Day Range
NZD 36.1736.93
52-Week Range
NZD 31.0238.60
Bid/Ask
NZD 36.17 / NZD 36.90
Market Cap
NZD 7.18 Bil
Volume/Avg
79,714 / 135,282

Key Statistics

Price/Earnings (Normalized)
23.22
Price/Sales
0.49
Dividend Yield (Trailing)
3.21%
Dividend Yield (Forward)
3.33%
Total Yield
3.21%

Company Profile

Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government’s Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
Sector
Healthcare
Industry
Medical Distribution
Stock Style Box
Mid Core
Total Number of Employees
5,000

Competitors

Valuation

Metric
EBO
SIG
CAH
Price/Earnings (Normalized)
23.2214.99
Price/Book Value
2.663.69
Price/Sales
0.490.750.12
Price/Cash Flow
18.6412.28
Price/Earnings
EBO
SIG
CAH

Financial Strength

Metric
EBO
SIG
CAH
Quick Ratio
0.551.170.48
Current Ratio
0.951.740.98
Interest Coverage
4.720.5824.55
Quick Ratio
EBO
SIG
CAH

Profitability

Metric
EBO
SIG
CAH
Return on Assets (Normalized)
4.51%−0.12%4.13%
Return on Equity (Normalized)
12.50%−0.23%
Return on Invested Capital (Normalized)
9.38%0.19%109.00%
Return on Assets
EBO
SIG
CAH

Medical Distribution Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
McKesson Corp
MCK
NtmcynsPdhnylg$62.9 Bil
Cencora Inc
COR
TyrqdcqhTtjtnt$43.1 Bil
Cardinal Health Inc
CAH
CrgchlfqfCwdzmqs$27.1 Bil
Shanghai Pharmaceuticals Holding Co Ltd Class H
SHPMF
Ypsjjxd$10.0 Bil
Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H
SHPMY
Bjnrcnw$10.0 Bil
Sinopharm Group Co Ltd
SHTDF
Xwbpjr$9.1 Bil
Sinopharm Group Co Ltd ADR
SHTDY
Przwrb$9.1 Bil
Amplifon SpA Az nom Post Frazionamento
AMFPF
Wnsjhy$6.4 Bil
Ebos Group Ltd ADR
EBOSY
Gydzqp$4.5 Bil
Medipal Holdings Corp ADR
MAHLY
Vrxb$3.7 Bil

Sponsor Center